Abstract:Abstract Background DNA methylation alteration is frequently observed in Lung adenocarcinoma (LUAD) and may play important roles in carcinogenesis, diagnosis, and prognosis. Thus, this study aimed to construct a reliable methylation-based nomogram, guiding prognostic classification screening and personalized medicine for LUAD patients. Method The DNA methylation data, gene expression data and corresponding clinical information of lung adenocarcinoma samples were extracted from The Cancer Genome Atlas (TCGA) database. Differentially methylated sites (DMSs) and differentially expressed genes (DEGs) were obtained and then calculated correlation by pearson correlation coefficient. Functional enrichment analysis and Protein-protein interaction network were used to explore the biological roles of aberrant methylation genes. A prognostic risk score model was constructed using univariate Cox and LASSO analysis and was assessed in an independent cohort. A methylation-based nomogram that included the risk score and the clinical risk factors was developed, which was evaluated by concordance index and calibration curves. Result We identified a total of 1362 DMSs corresponding to 471 DEGs with significant negative correlation, including 752 hypermethylation sites and 610 hypomethylation sites. Univariate cox regression analysis showed that 59 DMSs were significantly associated with overall survival. Using LASSO method, we constructed a three-DMSs signature that was independent predictive of prognosis in the training cohort. Patients in high-risk group had a significant shorter overall survival than patients in low-risk group classified by three-DMSs signature (log-rank p = 1.9E-04). Multivariate cox regression analysis proved that the three-DMSs signature was an independent prognostic factor for LUAD in TCGA-LUAD cohort (HR = 2.29, 95%CI: 1.47–3.57, P = 2.36E-04) and GSE56044 cohort (HR = 2.16, 95%CI: 1.19–3.91, P = 0.011). Furthermore, a nomogram, combining the risk score with clinical risk factors, was developed with C-indexes of 0.71 and 0.70 in TCGA-LUAD and GSE56044 respectively. Conclusions The present study established a robust three-DMSs signature for the prediction of overall survival and further developed a nomogram that could be a clinically available guide for personalized treatment of LUAD patients.

Identification of Prognostic DNA Methylation Signatures in Lung Adenocarcinoma

An integrative analysis of DNA methylation and gene expression to predict lung adenocarcinoma prognosis

Comprehensive analysis reveals the prognostic and immunogenic characteristics of DNA methylation regulators in lung adenocarcinoma

DNA Methylation Profiling Analysis Identifies a DNA Methylation Signature for Predicting Prognosis and Recurrence of Lung Adenocarcinoma

DNA Methylation Regulator-Meditated Modification Patterns Define the Distinct Tumor Microenvironment in Lung Adenocarcinoma

DNA methylation molecular subtypes for prognosis prediction in lung adenocarcinoma

DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications

A methylation-based nomogram for predicting survival in patients with lung adenocarcinoma

Prognostic Analysis of Lung Adenocarcinoma Based on DNA Methylation Regulatory Factor Clustering

DNA Methylation Analysis Identifies Clinically Relevant Lung Adenocarcinoma Subgroups

Identification of a novel prognostic DNA methylation signature for lung adenocarcinoma based on consensus clustering method

Identification of Diagnostic DNA Methylation Biomarkers Specific for Early-Stage Lung Adenocarcinoma.

Comprehensive analyses of genome-wide methylation and RNA epigenetics identify prognostic biomarkers, regulating the tumor immune microenvironment in lung adenocarcinoma.

Development and Validation of a DNA Methylation-related Classifier of Circulating Tumour Cells to Predict Prognosis and to provide a therapeutic strategy in Lung Adenocarcinoma

Integrative Analysis of DNA Methylomes Reveals Novel Cell-Free Biomarkers in Lung Adenocarcinoma.

Identification of DNA Methylation Signatures for Diagnosis of Lung Adenocarcinoma.

Identification of molecular subtypes in lung adenocarcinoma based on DNA methylation and gene expression profiling—a bioinformatic analysis

Identification of a Novel CpG Methylation Signature to Predict Prognosis in Lung Squamous Cell Carcinoma

A prognostic 11-DNA methylation signature for lung squamous cell carcinoma

A Novel Methylation-based Model for Prognostic Prediction in Lung Adenocarcinoma

Molecular subtypes based on DNA promoter methylation predict prognosis in lung adenocarcinoma patients